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Abstract 
Type I diabetes is considered a worldwide epidemic because its incidence is 
exponentially increasing. Current treatment of the disease requires blood glucose monitoring and 
intake of insulin.  While there have been many medical advances in devices that monitor glucose 
and deliver insulin, these treatments can still lead to complications, including but not limited to 
debilitating hypoglycemia, neuropathy, and death, if not followed properly.  To eliminate these 
complications, there is a need to create a novel approach for continuous and automated glucose 
monitoring and insulin delivery. This project seeks to address this challenge by creating a DNA 
nanostructure that can sense changes in the concentration of a target biomolecule. The long-term 
goal is to use this DNA nanostructure to detect a glucose-protein complex. The nanostructure 
comprises a DNA hinge with aptamers (short DNA strands with sequences that bind to a specific 
protein). Initial development and optimization experiments will target the protein thrombin for 
simplicity and easy availability. We use transmission electron microscopy (TEM) to measure the 
equilibrium changes in conformation of the hinge upon contact with thrombin. We initially 
explored two conformations of the hinge: one that opens when it comes into contact with 
thrombin and another that closes. Preliminary TEM results have shown that the closed structure 
is more efficient for detection.  In the future, we plan to conduct fluorescence experiments to 
further optimize the protein sensor and measure real-time response. These experiments will lay 
the foundation for a viable long-term glucose sensor; the sensor can then be paired with a 
molecular release mechanism to deliver insulin. Ultimately, this type of device could serve as an 
automated monitoring and delivery system that would make diseases such as diabetes more 
manageable and eliminate many of the complications that arise from current treatments.  
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Chapter 1: Introduction  
1.1 Type 1 and Type 2 Diabetes 
Diabetes Mellitus is a group of metabolic diseases that are characterized by excess 
glucose in the bloodstream. The presence of the excess glucose is due to the deficiencies 
in insulin secretion, insulin action or both. The vast majority of cases of diabetes fall into 
two categories: type 1 diabetes and type 2 diabetes. The cause of Type 2 diabetes is both 
a resistance to insulin action and a deficiency in insulin secretion. Also known as 
immune-mediated diabetes, Type 1 diabetes is caused by the absence of insulin secretion. 
Type 1 diabetes (T1D) is the motivation for this study. This is because it is the more 
severe form of diabetes and because large epidemiologic studies have shown the 
incidence of T1D is increasing by 2-5% worldwide with a prevalence of 1 in 300 in the 
US by 18 years of age. Currently, T1D accounts for 5-10% of total cases of diabetes 
worldwide and continues to be the most common type of diabetes in children and 
adolescents1. The immunological destruction of the beta cells, the insulin-producing cells 
in the pancreas, causes the absence of insulin secretion with T1D. Researchers now 
believed that both genetic and environmental triggers are involved in causing the disease 
and does not result from diet or lifestyles2.  Figure 1 below illustrates how the absence of 
insulin can affect the the uptake of glucose by individual cells.  
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As seen in the diagram, in a normal individual, the insulin binds to a receptor on the cell 
membrane and allow for the creation of glucose transporters that transport glucose into the 
cell. In an individual with T1D, there is no insulin available to bind to the receptors on the 
cell surface; with no insulin, glucose transports cannot bind to the cell membrane to transport 
glucose into the cell, so the cell cannot use the glucose for ATP generation. There is no cure 
for Type 1 diabetes. Current forms of treatment only seek to control the disease3.  
1.2 Current Treatment and Consequences of Treatment 
The typical treatment for T1D consists of insulin intake, carbohydrate counting, 
frequent blood sugar monitoring, eating healthy foods, and exercising regularly to 
maintain a healthy weight. The goal is to keep as close to a normal blood sugar level as 
possible4. Insulin intake is performed via injections or an insulin pump5 because oral 
intake of insulin results in degradation of the protein by stomach enzymes4. There are 
multiple forms of insulin, including rapid-acting insulin, long-acting insulin, and 
intermediate options. Insulin injections have to be taken several times a day and require 
Figure 1: Diagram of normal individual to Type 1 diabetic individual. In a normal individual, the insulin allows 
glucose to enter the cell by binding to the cell membrane to allow transport of glucose into the cell. In a T1D 
individual, there is no insulin to bind to the cell membrane, and glucose cannot be transported into the cell. 
	 3	
syringes and needles as well as different types of insulin depending on how much insulin 
is needed at a certain time of day6. Figure 2 below shows the different types of insulin 
and the conditions when they are used. 
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Figure 2: Chart of the Different Forms of Insulin. There are five different forms of insulin: rapid-acting, short-acting, 
intermediate-acting, long-acting, and premixed. Each form of insulin has a different onset, peak, and duration. They also 
control blood glucose levels in different ways6.   
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An insulin pump, on the other hand, is a small computerized device that delivers 
insulin into the body. The pump can be programmed to deliver continuous doses of 
insulin as well as specific doses through the day, usually around meals7. 
Both of these treatments come with their own disadvantages. While injections 
require less training on the part of the patient and are cheaper to purchase, low blood 
glucose levels can occur due to using different forms of insulin and having to self-
monitor when to administer the injections. Additionally, due to frequent injections, 
certain parts of the body can become resistant areas where insulin will not absorb 
properly8. While the insulin pump eliminates individual injections, allows more 
flexibility in diet, and delivers insulin more accurately than injections, it still has some 
disadvantages. Since a catheter needs to be attached to the patient to deliver insulin to the 
body, the pump can cause diabetic ketoacidosis (DKA) if the catheter comes out and no 
insulin is delivered. Additionally, there is a large learning curve associated with the 
pump, especially for children since to learn how to properly utilize and calibrate the 
pump, patients need to stay overnight in a hospital or spend a whole day in an outpatient 
center9.  Without proper training, patients can misuse the pump, resulting in 
complications that require hospitalization10. 
For glucose monitoring, there are also two options: finger-stick glucose 
monitoring or continuous glucose monitoring. The finger-stick method consists of taking 
small blood samples on test strips and using a portable meter to measure blood glucose 
levels. The test strip enzymes that bind glucose; the amount of enzymes bound to glucose 
determines the measured blood glucose level displayed on the portable meter. While this 
technology is improving to make blood glucose monitoring easier and faster, there are 
	 6	
still problems with the accuracy and specificity. For example, a true glucose level of 55 
mg/dl could yield a reading as low as 40 mg/dl or as high as 70 mg/dl. The inaccuracy in 
the reading leads to inaccurate insulin consumption and can cause hypoglycemic or 
hyperglycemic states. Additionally, the glucose test strips can also be problematic 
depending on the enzyme present on the strip. Certain enzymes used to create the test 
strip do not solely bind to glucose. For example with glucose dehydrogenase 
pyrroloquinoline quinone (GDH-PQQ), it can bind to a number of other sugars besides 
glucose, causing inaccurate readings to occur with the finger-stick method. Patients do 
not always know what interfering sugars exist and can take glucose measurements while 
consuming interfering sugars. This can lead to hypoglycemia and even death if not caught 
early enough. There is also pain associated with having to take numerous blood samples 
in a day 11.  
The continuous glucose monitoring (CGM) systems use a sensor inserted under 
the skin to check glucose levels in tissue fluid. The sensor stays in place for several days 
to a week, and then it must be replaced. The transmitter sends a signal from the sensor to 
the wireless monitor. To calibrate the device, the patient still has to use the finger-stick 
method. While CGM systems provide real-time measurements of glucose levels, there are 
more inaccurate and unreliable than the finger-stick monitors. Additionally, they are very 
expensive12.  
As discussed before, the goal of all T1D treatments is to maintain as close to 
normal blood glucose levels as possible. If a patient improperly manages their diabetes, 
then they can increase their risk of suffering from severe complications. T1D increases 
the risk for heart disease and vascular disease, heart attacks, stroke, and high blood 
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pressure. Excess sugar caused from improper insulin consumption can also cause 
neuropathy (nerve damage) since the excess sugar can damage the walls of capillaries 
that nourish the nerves. Kidney damage can occur since it also contains millions of tiny 
blood vessels that filter the blood. Severe damage can lead to kidney failure or 
irreversible end-stage kidney disease. Eye damage, foot damage, and skin and mouth 
conditions are additional complications that arise due to T1D13.   
1.3 Current Nanotechnology for Type 1 Diabetes 
Knowing the problems associated with current treatments of T1D, there is a need 
for novel treatments to be created. A possible resource for treatment is nanotechnology; 
this field offers sensing apparatuses that are more sensitive, accurate, and timely. 
Miniature devices that deliver insulin can also be created using nanotechnology14. The key 
to developing a functional nanotechnology-based device is to create one that mimics the 
body’s own glucose monitoring and insulin release capabilities as well as a device that 
does not elicit a strong immune reaction.  
Currently, there are a several nanotechnology treatments being developed for the 
treatment of T1D.  One of these new nanotechnology treatments is the microphysiometer. 
The microphysiometer is composed of nanotubes, which are several flat sheets of carbon 
atoms stacked and rolled into very small tubes. The nanotubes are electrically conductive, 
and the concentration of insulin in the chamber is related to the current at the electrode. 
These nanotubes work at physiological pH, and this sensor is able to detect insulin levels 
continuously by measuring the current (transfer of electrons) produced when insulin 
molecules oxidize in the presence of glucose. When the cells produce more insulin, the 
current in the sensor increases. This information can be transmitted to a wireless 
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computer and would allow for real time monitoring of insulin levels. This technology has 
the drawback of not directly measuring glucose, but rather measuring insulin.  
Another technology is the implantable sensor. This uses polyethylene glycol (PEG) 
nanospheres covalently bound to phenylboronic acid and attached to two flurophores to 
monitor diabetes blood sugar levels. The nanospheres are injected under the skin and stay 
in the interstitial fluid; they can be seen through the skin as a tattoo. In the absence of 
sugar, the nanospheres are small and can maintain close contact with the fluorophores. 
When sugar is present, it binds to the phenylboronic acid, which increases the size of the 
nanospheres. The larger nanospheres are not in close contact with the fluorophores, 
causing the nanospheres to dim. When the nanospheres dims, the tattoo fades, indicating 
an increase in blood glucose levels15.  
In terms of delivering insulin, polymeric nanoparticles are used as carriers of insulin. 
These are biodegradable, and have polymer-insulin matrix enclosed in a nano-porous 
membrane. A rise in blood glucose levels causes a decrease in the size of the molecules 
in the nanoporous membrane, resulting in biodegradation and release of insulin. One 
disadvantage with this technology is that the glucose/glucose oxidase reaction causes the 
pH to drop in the delivery system, which causes the swelling of the polymer system, 
leading to more insulin than necessary being released14. The polymeric nanoparticles can 
also adhere non-specifically to surfaces they are not intended to or become trapped in the 
mucus linings of the body. Table 1 below summarizes the advantages and disadvantages 
associated with polymeric membranes and other nanoparticle membranes.  
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 Table 1: Advantages and disadvantages of nanoparticle drug delivery systems. The systems included are polymeric 
nanoparticles, ceramic nanoparticles, gold nanoparticles, and liposomes.  
 
The table above also shows disadvantages for other types of nanoparticles that can be 
used in the delivery of insulin. While all of these nanoparticles can be used, they each 
have the potential to cause problems within the body, and therefore cannot yet be feasibly 
applied in vivo. Oral insulin is also a possibility if the insulin is used with polysaccharides 
and polymeric nanoparticles. Polysaccharides are naturally biodegradable by enzymes 
and have good biocompatibility. Since insulin taken orally without any membrane 
surrounding, it is degraded by gastric enzymes; the enveloped matrix of nanoparticles or 
polysaccharides are protecting it from the enzymes14. The oral route for insulin 
administration is considered to be the most convenient and comfortable, but there are still 
problems with using the membrane with oral insulin. Specifically, the problem is due to 
the intestinal epithelium being a major barrier to the adsorption of hydrophilic drugs. This 
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means another layer of molecules needs to be added to the membrane to allow it to 
function well within the intestines14.  
 Considering all the disadvantages involved with current nanotechnology, there 
still exists a need for a novel treatment for blood glucose monitoring and insulin 
consumption. To address this technology gap, we look to DNA origami to create a device 
capable to sensing glucose and releasing insulin. The goal of this work is to take the first 
step in developing this device by constructing a sensor that will generally sense proteins 
in solution. This study will, therefore, focus on the creation and optimization of a 
universal protein sensor. While this protein sensor can be used to detect a glucose-
enzyme complex in the treatment of T1D, the sensor can also be used to detect other 
proteins, such as hemoglobin.    
1.4 Introduction to DNA Origami 
Deoxyribose nucleic acid (DNA) consists of nitrogenous bases, five-carbon sugars, and a 
phosphate group. The structure DNA is shown in Figure 3 below.  
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Figure 3: The structure of DNA. The structure is well-defined with specific base pairing and helix turns. As shown, 
adenosine binds with thymine, and guanine binds with cytosine. Each helix turn is about 3.4 nm16.  
Foremost, DNA is known for encoding genetic information, but it also contains 
properties that allow it to be a good foundation for nanotechnology. Recently, DNA 
origami has emerged as a promising technique for assembling complex nanostructures. 
The design of DNA-based nanostructure relies heavily on the assembly properties of the 
bases. The field of DNA nanotechnology was originally established by Nadrian 
Seeman’s, a chemist and crystallographer at NYU. He explored junctions and lattices of 
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nucleic acids and initially demonstrated DNA nanoconstruction through the fabrication of 
a DNA molecular cube17,18.  
 Scaffold DNA origami, developed by Paul Rothemund in 2006, has dramatically 
widened the scope of DNA nanotechnology. In this approach, many short single-stranded 
DNA (“staples”) direct the folding of a long, circular single-stranded DNA (“scaffold”) 
into different structures. It is the sequences of the staples that will determine the final 
shape of the nanostructure. The scaffold is typically derived from the single stranded 
genome of the M13MP18 bacteriophage. A solution containing the scaffold and staples 
are heated to facilitate annealing in a thermal ramp. This method allows for high yield 
assembly of nanostructures with significantly greater geometric complexity than previous 
approaches. The first structures created with DNA origami included squares, rectangles 
disks, and five-pointed stars with dimensions in the 10-100nm range with a spatial 
resolution of 6 nm. As the technology continued to expand, modular “DNA jigsaw 
pieces”, nano-sized breadboards as templates for nanomaterials, and even three-
dimensional nanostructures have been made by stacking layers of double helices in a 
honeycomb or square lattice. Figure 4 below shows some of the structures originally 
created by Paul Rothemund using this technique19. 
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Figure 4: DNA Origami structures created by Paul Rothemund. The shapes include stars, smiley faces, triangles, and two 
differently routed rectangles. This shows the versatility of DNA Origami in producing unique nanostructures 
As shown in the figure, there are many options for creating structure using DNA origami. 
Recently, DNA nanotechnology has even demonstrated immense promise for 
applications such as drug delivery. The Trojan Horse developed by the Nanoengineering 
and Biodesign Lab (NBL) has proven to be an effective approach to circumvent drug 
resistance in leukemia cells. The structure is able to enter cells via endocytosis and 
bypass defenses in the cell membrane against the free drug20. Additionally in 2012, 
Shawn Douglas developed an autonomous DNA nanorobot that could deliver a payload 
to cells upon triggered activation21. As the field grows, a major focus is developing tools 
to track and treat diseases such as diabetes. 
1.5 Significance 
As of 2011, 266 million people worldwide are affected by Type 1 diabetes, and this 
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number is expected to rise to 552 million by 2030. In the United States, diabetes is the 7th 
leading cause of death. Additionally, it can increase the risk of heart disease by 2-4 times, 
lower life expectancy by up to 15 years, and is the leading cause of kidney failure, lower 
limb amputation, and adult on set blindness. The estimated financial cost of diabetes is 
the US in 2007 was $174 billion, which includes the costs of premature death, disability, 
and medical care. In 2012, the cost increased to $249 billion22. Additionally, more and 
more people are being diagnosed with diabetes. The incidence of the disease in young 
people to set to increase by 49% over the next 40 years23.  Diabetes research can 
significantly improve the quality of life and the life expectancy of people diagnosed with 
Type I diabetes.  In last 50 years of diabetes research, researchers have found ways to 
produce human insulin from microorganisms, develop insulin pumps to deliver 
continuous insulin to patients to help avoid hypoglycemia, and invent a non-invasive 
A1C, which measures average blood glucose levels over a three-month period. Further 
research into the establishment of a continuous glucose monitor and insulin delivery 
sensor can significantly improve the economic costs and the human costs of this disease; 
more people suffering from diabetes would be able to live longer and reduce 
complications that arise from diabetes24.  More broadly, the creation of a protein 
biosensor would mitigate the high demand for methodologies for detecting and 
identifying specific proteins in biological and environmental samples.  
1.6 Thesis Objective and Hypothesis 
The objective of this thesis is to develop and optimize a universal protein sensor 
than can eventually be applied to a glucose-protein complex in the measurement of blood 
glucose levels needed for T1D. The creation of a protein sensor with DNA origami offers 
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many advantages over other nanotechnologies. DNA origami offers unprecedented 
control over nanoscale geometry and biochemical function as well as controlled delivery 
of medicine and fluorescent-based imaging applications25.  By creating a protein sensor 
through DNA origami, there is inherent biocompatibility and absence of cytotoxicity. The 
protein sensor will also alleviate some of the struggles and complications associated with 
T1D since the protein sensor will be able to mimic natural glucose monitoring 
mechanisms in the body.   
The study looks at two configurations of the DNA protein sensor as well as two 
different environmental conditions. The protein sensor is tested with thrombin, a protein 
used in blood coagulation, because of how highly studied the protein is and its 
availability. It is hypothesized that the protein sensor will work well in both closed-to-
open configuration and the open-to-close configuration, and the protein sensor will work 
better in the buffer most consistent with physiological conditions. Ultimately, the 
optimization of this device will allow for further application with glucose.  
1.7 Thesis Overview 
This thesis includes four chapters. Chapter 1 is the relevant background and motivation 
for the project. Chapter 2 covers methodology, and chapter 3 details the results. Chapter 4 
includes conclusions and future work. References are included at the end of the 
document, and there is a table of figures and tables in the front of the document.  
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Chapter 2: Thrombing-Binding Protein Sensor Methodology  
2.1 Modification of structure 
  The original DNA structure, the hinge, was designed in the Nanoengineering and 
Biodesign Lab (NBL). The hinge consists of two stiff bundles of 18 double-stranded 
DNA helices connected at one end by 6 single-stranded connections. The hinge is known 
to show resistance to small and large angles and has relative flexibility in the range 
between 40° and 80°26. The structure was designed used caDNAno and is shown below in 
Figure 5.  
 
Figure 5: caDNAno 2 Design. The hinge is composed of different staples and is shown in different colors. The structure 
was originally designed by Alexander E. Marras in the Nanoengineering and Biodesign Lab 
  
The structure was then modified to act as a universal protein sensor through the use of 
overhanging staples and aptamers (short ssDNA sequences that bind to pre-selected 
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targets, such as proteins with high specificity and affinity27). The modification depends 
on the configuration of the hinge. There are two configurations used: the closed default 
hinge and the open default hinge. The closed default hinge is shown in Figure 6 below.  
 
Figure 6: The Closed Default Hinge. The hinge contains one thrombin-binding aptamer (purple) and a complimentary 
sequence to the aptamer (pink). The binding of these two DNA sequences causes the hinge to be closed in the absence of 
thrombin.  
The figure shows two complimentary strands that are bound to each in their natural state. 
The purple strand is the thrombin-binding aptamer while the pink strand is a 
complementary sequence. In the absence of thrombin these two sequences bind to each 
other and cause the hinge to remain closed. The aptamer and its complementary sequence 
are located at the end of two overhanging staples that come off the arms of the hinge.  
 The opened default hinge is shown in Figure 7 below.  
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Figure 7: The Opened Default Hinge. The hinge contains two thrombin-binding aptamers (purple). The aptamers are not 
complementary to each other, causing the hinge to remain open. 
The figure shows two thrombin-binding aptamers (purple) located on the overhanging 
staples of the arms of the hinge. The aptamers are not complementary to each other, and 
therefore, all the hinge to stay in the open position in the absence of thrombin.  
2.2 Thrombin-binding Aptamer 
  The thrombin-binding apatamer (TBA) is shown in Figure 8 below. 
 
Figure 8: Diagram of the Secondary Structure of the TBA and Its Interaction with Thrombin. (A) shows the secondary 
structure of TBA. (B) and (C) show the interaction of TBA with the thrombin anion exosite I according to X-ray and 
NMR, respectively28.  
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In Figure 8, (A) show the secondary structure of the TBA. This structure, as shown in (B) 
and (C), can attach to multiple amino acids via hydrogen bonding in a binding pocket of 
thrombin. This binding of TBA to thrombin allows the aptamer to be used as signaling 
system to indicate the presence of thrombin in solution. Any modifications to the 
secondary structure of TBA or the binding pocket of thrombin leads to poor or no 
binding.  
2.3 Folding Reaction, Characterization, and Purification  
 The hinge was folded using previously defined methods29. The scaffold used was 
an 8064 base scaffold; it is a variant of the M13MP18 circular ssDNA genome. The 
scaffold is placed in solution at final concentration of 20 nM in a folding buffer 
containing 0.5x Tris and EDTA (TE), 5 mM NaCl, 18 mM MgCl2, and water as well as 
the designed staple strands that are ordered commercially. Each staple is placed in the 
solution at a 10-fold excess at 200 nM compared to the scaffold. An 18 hour and a 2.5 
day thermal ramp were run on separate folding reactions. Each thermal ramp involves 
rapid heating to 65°C and slowly cooling to 4OC to facilitate the self-assembly process. 
The folding reaction was subjected to agarose gel electrophoresis to determine if the 
products were well-folded nanostructures. Based on the degree of folding, an optimal 
thermal ramp could be chosen. 
Following this characterization via gel electrophoresis, multiple solutions with 
scaffold and staples were folded again using the optimal thermal ramp. The products of 
the folding reaction were then purified to remove the excess staple strands. This involved 
adding an equal volume of 15% polyethylene glycol (PEG) 8000 into the folding reaction 
and centrifuging at 1600g for 30 minutes at 4°C. The PEG polymers act as a separating 
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agent and cause the excess staples to separate from the DNA Origami structure in the 
solution30. The supernatant containing the excess staples was removed, leaving behind a 
pellet containing the folded structure. The pellet was resuspended in a solution of 10 mM 
TE and 18mM MgCl2.  
2.4 Gel Electrophoresis 
 Agarose gel electrophoresis was used to initially verify properly folded structure. 
The folding reaction was run through a 2% agarose gel in the presence of 0.5X TBE and 
11mM MgCl2. The gels were run at 70V for 4 hours to allow time for band separation. 
The resulting gel was imaged and certain bands were excised for Transmission Election 
Microscopy (TEM).  
2.5 Transmission Electron Microscopy 
 To further understand the degree of folding and functionalization, the 
nanostructures were imaged via transmission electron microscopy (TEM). The products 
of the gel electrophoresis were placed on copper mesh grids and negatively stained with 
Uranyl Formate (UFo)29. 3.40 µL of the sample was placed on the grid and incubated for 
4 minutes. The sample was wicked away and negatively stained with 10 µL and 20 µL of 
UFo. The UFo was incubated for 10 seconds before being wicked away. A FEI Tecnai 
G2 Spirit TEM, which uses and electron acceleration voltage of 80kV, was used to image 
the nanostructures. The structures were images at 50,000x magnification.  
2.6 Buffer Conditions  
 To understand ideal buffer conditions for the thrombin protein sensor, two 
different buffers were made. The resuspension buffer was the foundation of the two 
buffers, and it contained 2M Tris-HCl, 1.375 mM MgCl2, Bovine Serum Albumin (BSA) 
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and enough Phosphate-Buffered Saline (PBS) for a total volume of 50 mL.  For the 
binding buffer containing 140 mM NaCl, 2.762 mL of the resuspending buffer was added 
to .0492 mL of 4 M NaCl. For the binding buffer containing 200 mM NaCl, 2.671 mL of 
the resuspending buffer was added to .140 mL of 4 M NaCl. The 140 mM NaCl 
concetration was chosen because proteins are at their optimal functionality at this 
concentration and below. The 200 mM NaCl concentration was chosen because DNA 
irigami structures are at their optimal functionality at this concentration to up to 2 M 
NaCl. 2.811 mL of pure thrombin were added to each binding buffer to obtain a 
concentration of 10mM thrombin in solution. The thrombin-binding buffers were then 
aliquoted into specific volumes, flash frozen, and placed in a -80°C freezer for future use. 
Folding reactions were run again through an ideal thermal ramp, and the PEG products 
were resuspended this time in each of the binding buffers. Thrombin titrations were then 
done to see the effects of thrombin on each of the sensors.  
2.7 Thrombin Titrations 
  To titrate the thrombin with the DNA protein sensors, a serial dilution of 
thrombin was first completed. An allotment of thrombin-binding buffer was taken from 
the freezer and diluted in either the 200 mM NaCl binding buffer or the 140 mM NaCl 
binding buffer. The dilutions were as follows: 10mM thrombin, 1 mM thrombin, 100 µM 
thrombin, 10 µM thrombin, 6 µM thrombin, 600 nM thrombin, 200 nM thrombin, 60 nM 
thrombin, 20 nM thrombin, and 2 nM thrombin. The titrations placed equal volumes of 
the protein sensor and the thrombin in solution to obtain the following solutions: 300 nM 
thrombin, 100 nM thrombin, 30 nM thrombin, 10 nM thrombin, and 1 nM thrombin. The 
degree of functionalization of the sensor was then recorded through TEM imaging.  
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2.8 Angular Distributions 
 In the presence of thrombin, the Closed Default Hinge should open as shown in 
Figure 9 below.  
 
  
 
 In the figure above, the thrombin (red) is introduced to the hinge in solution. The 
half circle shown in the figure indicates the necessary secondary structure formation of 
the aptamer to bind to thrombin. The thrombin binds to the thrombin-binding aptamer 
(purple), which causes the thrombin-binding aptamer to unbind from the complementary 
sequence (pink) on the other overhanging staple. This allows the hinge to open.  
 In the presence of thrombin, the Opened Default Hinge should close as shown in 
Figure 10 below.  
 
 
 
Figure 9: The Closed Default Hinge in the Presence of Thrombin. The Closed Default Hinge is introduced to thrombin (red) in 
solution. The thrombin then binds to the thrombin aptamer and opens the Closed Default Hinge. 
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Figure 10: The Opened Default Hinge in the Presence of Thrombin. The Opened Default Hinge is introduced to thrombin 
(red) in solution. The thrombin then binds to the two thrombin aptamers (purple) and closes the hinge.  
In the figure above, the thrombin (red) is introduced to the hinge in solution. The 
thrombin binds to the thrombin-binding aptamers (purple), which causes the two arms of 
the hinge to come together. This causes the hinge to close.  
To ensure there was a baseline comparison when changes were made in thrombin 
concentration, a control hinge was also designed. This control hinge is shown in Figure 
11.  
 
Figure 11: The Control Hinge in the Presence of Thrombin. The Control Hinge is introduced to thrombin (red) in 
solution. The thrombin has no place to bind, and therefore, there is not configurational change in the Control Hinge 
In the figure above, the thrombin (red) is introduced to the hinge is solution. This hinge 
contains no thrombin aptamers or overhanging staples. This means that even in the 
presence of thrombin, there will be no change in the configuration.  
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 To test the functionality and optimize the protein sensor, the hinges were 
introduced to the thrombin titration solutions. Images of the hinges were taken on the 
TEM after they interacted with thrombin, and individual angles of the hinges were 
measured using the angle measuring tool in ImageJ. The individual measurements were 
complied to create distributions in MatLab. The distributions from each configuration 
were compared against each other to understand the changes resulting from buffer 
conditions and the presence of thrombin.  
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Chapter 3: Results and Discussion  
3.1 Gel Electrophoresis 
Gel electrophoresis separates structures based on size. The smaller structures will 
run through the gel faster than the larger structures. Looking at the differences in 
separation, we can tell if the hinges are well folded.  
Figure 10 below shows the results of the 18-hour thermal ramp used to fold the 
DNA origami.  
  
 
 
 
 
 
 
 
 
 
 
 
 
   
Ladder 
Scaffold 
Structure 
Excess Staples 
Figure 12: Gel Electrophoresis for Structures Folded in 18-hour Thermal Ramp. The three different hinges are 
folded in an 18-hour thermal ramp. A sample of the folded structures are placed in individual wells to test how well 
folded the structures are. 1 refers to the control hinge, 2 refers to the closed default hinge, and 3 refers to the opened 
default hinge. 
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The gel pictured in the figure above shows the accuracy of folding for each of the three 
different configurations of the hinge. The Control Hinge is in the lane marked 1, the 
Closed Default Hinge is in the lane marked 2, and the Opened Default Hinge is in the 
lane marked 3. On the far left of the gel, a 1kb ladder was run as a reference. A scaffold 
of 8064 bases was run on the next lane to also act as a reference point for the folded 
structures. The farthest and brightest band at the end of the gel corresponds to the excess 
staples, which are much smaller than the other structures. This gel shows there are three 
bands coming from lanes 1-3. The first and the second band from the top show improper 
folding; the third, fastest-running, and brightest band shows well-folded structures. This 
band moves slightly farther than the scaffold because the folded structures are more 
compact than the scaffold. This gel indicates that the hinges are folded well and that they 
can be folded using an 18-hour thermal ramp.  
Figure 13  below shows the results of a 2.5-day thermal ramp.  
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The gel pictured in the figure above contains a 1 kb ladder and 8064 scaffold run in the 
second lane. Lanes 1 and 2 contain the Control Hinge, lane 3 and 4 contain the Closed 
Default Hinge, and lane 5 and 6 contain the Open Default Hinge. There again exists a 
bright narrow band corresponding to each well that contains the structure that shows 
well folded structures. There is another band above the bright and narrow band that 
shows improper folding. Overall, this gel indicates the structures are well folded, but not 
significantly better folded than they are using an 18-hour thermal ramp.  
3.2 Transmission Electron Microscopy Results 
 To verify the well folded structure, the gel bands were excised and imaged under 
TEM. Figure 14 below shows the results of imaging one of the gel bands.  
  
Figure 13: Gel Electrophoresis for Structures Folded in 2.5 Day Thermal Ramp. The gel is run to test how well 
folded the strucutres are. Lanes 1 and 2 refer to the Control Hinge. Lanes 3 and 4 refer to the Closed Hinge, 
and lanes 5 and 6 refer to the Opened Hinge 
	 28	
 
Figure 14: TEM Image of Gel Band from Open Default Hinge in 18-hour Ramp. The hinges here are open in the absence 
of thrombin and show that the structures are well folded and functional. Scale bars 50 nm.  
In the figure above, the TEM allows for visualization of the structures to determine if 
they are well folded. The image shows the Opened Default Hinge after an 18-hour 
thermal ramp. The hinge is in the open position as well as in the proper form of the hinge. 
This image reconfirms the use of an 18-hour thermal ramp to fold the structures. 
The TEM is also used to image the results of the thrombin titration solutions. 
Figure 15 below shows the result of placing the Control Hinge in the thrombin titration 
solutions containing 140 mM NaCl.  
 
 
 
 
 
 
 
a)	 b)	
Figure 15: The Control Hinge in 140 mM Nacl Solution with 0 nM thrombin and 10 nM 
thrombin. A depicts the Control Hinge with there is no thrombin is in solution and B represents 
when there is 10 nM thrombin in solution.  Scale Bars 50nm 
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The figure above shows the Control Hinge when no thrombin is present (left) and when 
10 nM of thrombin (middle and right) is present in solution. Under the TEM, the hinge 
does not change configuration when thrombin is added, which verifies the functionality 
of the Control Hinge.  
Figures 16 and 17 below show the Closed Default Hinge and the Opened Default 
Hinge in the 140 mM solution when thrombin is present and when thrombin is absent.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figures 16 and 17 show the Opened Default Hinge and Closed Default Hinge when there 
is no thrombin present (left) and when 30 nM of thrombin is present (middle and right). 
The TEM image shows that most Opened Default Hinge structures are open when there is 
a)	 b)	
a)	 b)	
Figure 16: The Opened Default Hinge in 140 mM NaCl solution with 0 and 30 nM thrombin. 
(A) depicts when there is no thrombin and (B) depicts when there is 10 nM of thrombin in 
solution. Scale Bars 50nm 
Figure 17:  The Closed Default Hinge in 140 mM NaCl solution with 0 and 30 nM thrombin. (A) 
depicts when there is no thrombin and (B) depicts when there is 10 nM of thrombin in solution. 
Scale Bars 50nm 
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no thrombin present. Not all the structures were open, however, and this could be due to 
the presence of misfolded structures. TEM images of the Closed Default Hinge show 
mostly closed when no thrombin is present. The presence of open structures could be due 
to the location of the aptamers on the hinge. Also the open hinge has a wide range of 
motion (from 0° to 180°); the hinge will not close if the aptamer is not in close proximity 
to the complementary sequence, leading to open structures. The Opened Default Hinges 
does show evidence of closing when thrombin is introduced, but there are still open 
structures. The Closed Default Hinge opens when the thrombin is introduced, and while 
there are closed structures present, there did not appear to be as many nonfunctional 
structures are there were with the Open Default Hinge. The presence of nonfunctional 
structures in thrombin solutions prompted the need to further characterize the degree of 
functionality of the Closed Default Hinge and the Opened Default Hinge.  
3.3 Angular Distribution Results  
To quantitatively characterize the different configurations of the hinges, angular 
distribution measurements were made using ImageJ. This is show in Figure 18.  
 
 
 
 
 
 
 
 
Figure 18: TEM Image with Angle Measurement. 
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The individual angle measurements of the TEM images where complied in 
Matlab. These angle measurements were then used to plot an angular distribution of each 
hinge configuration in the presence and absence of thrombin. Figures 19, 20, and 21 
show these angular distributions of the different configurations of the hinge in 140 mM 
NaCl.  
 
 
 
 
  
Figure 19: The Angular Distribution of the Control Hinge in 140 mM NaCl in Different Thrombin 
Concentrations. The distributions of the figures do not change as the thrombin concentration is increased. 
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Figure 20: The Closed Default Hinge in 140 mM NaCl in Different Concentrations of Thrombin. The 
distribution shows a shift to the right as the thrombin concentration increases. 
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Figure 21: The Opened Default Hinge in 140 mM NaCl in Different Concentrations of Thrombin. The distributions either 
stay the same or shift to the right as the thrombin concentrations increase. 
Figure 19 shows the distribution of the Control Hinge doesn’t change as the 
concentration of thrombin is increased. This shows that this hinge functions correctly and 
that the DNA origami structure itself is not affected by the presence of the protein. Figure 
20 shows the distribution of the Closed Hinge shifts to the right as the concentration of 
thrombin increases. The Closed Default Hinge should not have a wide distribution 
(ranging from 10° to 180°) when no thrombin is present because all Closed Default 
Hinge structures should have an angular measurement of under 10°. Normally, an open 
hinge has a large angular distribution/motion. This shows we do not have a high 
efficiency of closing. The presence of this wide distribution results from the hinge’s 
inability to move into a position where it was possible for it to close. The connections on 
the vertex of hinge can be too stiff for the hinge to have a large range of motion, causing 
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the hinge to average around 50°.  However, when thrombin is present, the “under 10°” 
angular distribution decreases and the probably of the “10° to 180°” angular distribution 
increases. This is what is noted as a shift in distribution, and this shows that this hinge 
functions correctly and is able to sense when thrombin is in solution. The hinge also 
shows slight sensitivity to the concentration of thrombin in solution. Figure 21 shows the 
distribution of the Opened Default Hinge doesn’t change or shifts to the right as the 
concentration of thrombin increase. This shows that this hinge does not function correctly 
because the hinge does not close as it should when thrombin is introduced. The 
distributions for the Control and Closed Default Hinge also show that the buffer 
conditions work well, indicated by the presence of uniform distribution of the Control 
Hinge and a shift in distribution of the Closed Default Hinge, for the hinge functionality.  
 Figures 22, 23 and 23 show the angular distributions of the hinge at different 
concentrations of thrombin in 200 mM NaCl.  
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Figure 22: The Angular Distribution of the Control Hinge in 200 mM NaCl in Different Thrombin 
Concentrations. The distributions of the figures do not change as the thrombin concentration is increased. 
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 Figure 23: The Closed Default Hinge in 200 mM NaCl in Different Concentrations of Thrombin. The 
distribution shows a shift to the left as the thrombin concentration increases 
Figure 24: The Opened Default Hinge in 200 mM NaCl in Different Concentrations of Thrombin. The 
distributions either stay the same as the thrombin concentrations increase. 
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Figure 22 shows that in the 200 mM NaCl, the angular distribution of the Control Hinge 
stays the same as the thrombin concentration increases. The uniform nature of the 
probability distribution shows that the Control Hinge is functioning well regardless of 
how much thrombin is present in solution. Figure 23 shows that the angular distribution 
of the Closed Default Hinge shifts to the left as the concentration of thrombin increases. 
The Closed Default Hinge gains an even higher “under 10°” angular distribution with 
increasing thrombin concentrations. This is defined as a shift to the left, showing that the 
hinge is working contradictory to what we expect. This could be due to salt screen 
effects; the aptamer is only 23 base pairs long, so the excess salt warps the intended 
secondary structure needed for binding. Another possible source for the problem could be 
due to the breakdown of the tertiary structure of thrombin, causing a deformation of the 
aptamer binding pocket. Figure 24 shows that the angular distribution of the Opened 
Default Hinge also stays the same as the concentration of thrombin increases. This shows 
that this particular configuration is not working because it is not becoming more closed as 
the concentration of thrombin increases.  
 The 200 mM NaCl buffer conditions are shown to not be ideal because while it 
causes the same results in the Control and Opened Default Hinge, it caused the Closed 
Default Hinge to lose its functionality. This loss of functionality is attributed to the low 
salt threshold of thrombin. Since thrombin doesn’t function well in this high of a salt 
concentration, it starts to aggregate, which causes low binding affinity problems with the 
hinge structure. This aggregation is shown in Figure 25 below.  
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Figure 25: Aggregation of Thrombin and Hinges. In the left image, the pink circle indicates the position of a 
thrombin aggregate in the 200 mM NaCl solution. In the right images, aggregations of Closed Default Hinges  
are seen in the presence of thrombin in 200 mM NaCl solution. 
  The angular distributions led to the conclusion that the 140 mM NaCl solution is the 
ideal buffer and the Closed Default Hinge is the more optimized protein sensor.  
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Chapter 4: Conclusions and Future Work 
 The development of a universal protein sensor is relevant to the treatment of Type 1 
diabetes. Current methods of treatment cause numerous complications, and if they are not used 
properly, they can lead to several other diseases, including neuropathy, nephropathy, and even 
death.  The universal protein sensor would be able to detect the presence of glucose in the blood, 
allowing for monitoring blood glucose levels without the need for a continuous glucose 
monitoring system and without drawing multiple blood samples a day to measure blood glucose 
levels. Novel nanotechnology known as DNA origami can be used to create and optimize this 
universal protein sensor.  
 DNA origami allows for the creation of unique structures through the specialized folding 
of DNA. Using this technique, a hinge structure can be created that contains small DNA strands 
(aptamers) that have a high affinity and high specificity for thrombin. The hinge structure comes 
in three configurations. The Control Hinge contains no aptamers and does not interact with 
thrombin. The Closed Default Hinge contains aptamers that allow it to go from the closed 
configuration to the open configuration upon contact with thrombin. The Opened Default Hinge 
goes from open to close when thrombin is present. Between the Closed and the Opened Default, 
the Closed Default functions better in solution and is actually able to open in the presence of 
thrombin whereas the Opened Default does not close in the presence of thrombin. A 140 mM 
NaCl solution and a 200 mM NaCl solution are used to determine the ideal buffer conditions. 
The 140 mM NaCl is the more ideal buffer because it does not cause the aggregation of thrombin 
and allows for the thrombin to bind to the aptamers. 
 Future experiments will go forward with the Closed Default Hinge Structure. The design 
will be corrected to allow for more opening of the structures in thrombin solution, so that there is 
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minimal closed structure when thrombin is introduced. One way to improve the structure is to 
create a complementary strand that has lower affinity for the aptamer. To lower the affinity of 
the complementary strand, the nucleotide sequence can be changed to contain lesser 
complementary base pairs.   The design will also include a quencher-fluorophore system, such as 
the one shown in Figure 26.  
 
Figure 26: Quencher-Fluorophore system on Closed Default Hinge. The quencher (black hexagon) blocks the emission of 
the fluorescence (blue) when the hinge is closed and no thrombin (red) is present. When thrombin is introduced and the 
hinge opens, the quencher moves away from the fluorescence, and the signal fluoresce.  
 
The quencher will quench the fluorescence when there is no thrombin and the hinge is closed. 
The quencher moves away from the fluorescence when thrombin is present and the observed 
intensity of the fluorophore molecule increases. A similar measurement approach was previously 
used to detect conformational changes of a DNA origami mechanism26. With the addition of the 
quencher-fluorophore system, the speed of the hinge opening and closing can be measured in 
real-time. This allows us to measure the reaction time of the hinge to the presence of thrombin 
and further characterize functionality.  
 Ultimately if this universal protein sensor can be functional within live tissue and with 
the human body, it can replace current methods of blood glucose monitoring. The sensor has less 
complications associated with it, and it functions more closely to the natural blood glucose 
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detection system within the body. This can alleviate many of the problems diabetics have and 
give them a higher quality of life.  
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